Plasma protein biosignatures for detection of cardiac allograft vasculopathy

Background Coronary angiography remains the most widely used tool for routine screening and diagnosis of cardiac allograft vasculopathy (CAV), a major pathologic process that develops in 50% of cardiac transplant recipients beyond the first year after transplant. Given the invasiveness, expense, dis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of heart and lung transplantation 2013-07, Vol.32 (7), p.723-733
Hauptverfasser: Lin, David, PhD, Cohen Freue, Gabriela, PhD, Hollander, Zsuzsanna, PhD, John Mancini, G.B., MD, FRCPC, Sasaki, Mayu, MPH, Mui, Alice, PhD, Wilson-McManus, Janet, BS, MT(ASCP), Ignaszewski, Andrew, MD, FRCPC, Imai, Carol, BSN, Meredith, Anna, BS, Balshaw, Robert, PhD, Ng, Raymond T., PhD, Keown, Paul A., MD, DS, Robert McMaster, W., PhD, Carere, Ron, MD, FRCPC, Webb, John G., MD, FRCPC, McManus, Bruce M., MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Coronary angiography remains the most widely used tool for routine screening and diagnosis of cardiac allograft vasculopathy (CAV), a major pathologic process that develops in 50% of cardiac transplant recipients beyond the first year after transplant. Given the invasiveness, expense, discomfort, and risk of complications associated with angiography, a minimally invasive alternative that is sensitive and specific would be highly desirable for monitoring CAV in patients. Methods Plasma proteomic analysis using isobaric tags for relative and absolute quantitation–matrix-assisted laser desorption ionization double time-of-flight mass spectrometry was carried out on samples from 40 cardiac transplant patients (10 CAV, 9 non-significant CAV, 21 possible CAV). Presence of CAV was defined as left anterior descending artery diameter stenosis ≥ 40% by digital angiography and quantitatively measured by blinded expert appraisal. Moderated t- test robust-linear models for microarray data were used to identify biomarkers that are significantly differentially expressed between patient samples with CAV and with non-significant CAV. A proteomic panel for diagnosis of CAV was generated using the Elastic Net classification method. Results We identified an 18-plasma protein biomarker classifier panel that was able to classify and differentiate patients with angiographically significant CAV from those without significant CAV, with an 80% sensitivity and 89% specificity, while providing insight into the possible underlying immune and non-alloimmune contributory mechanisms of CAV. Conclusion Our results support of the potential utility of proteomic biomarker panels as a minimally invasive means to identify patients with significant, angiographically detectable coronary artery stenosis in the cardiac allograft, in the context of post-cardiac transplantation monitoring and screening for CAV. The potential biologic significance of the biomarkers identified may also help improve our understanding of CAV pathophysiology.
ISSN:1053-2498
1557-3117
DOI:10.1016/j.healun.2013.04.011